The World Health Organization's End TB Strategy prioritizes universal access to an early
diagnosis and comprehensive drug susceptibility testing (DST) for all individuals with …

The prevalence of tuberculosis (TB) remains the leading cause of death from a single
infectious agent, ranking it above all other contagious diseases. The problem to tackle this …

Drug-resistant Mycobacterium tuberculosis is a worldwide health-care problem rendering
current tuberculosis (TB) drugs ineffective. Drug efflux is an important mechanism in …

The latest WHO report estimates about 1.6 million global deaths annually from TB, which is
further exacerbated by drug-resistant (DR) TB and comorbidities with diabetes and HIV …

Objectives We described the prevalence of clofazimine (CFZ) resistance in a multidrug-
resistant tuberculosis (MDR-TB) cohort in China. We also aimed to identify dynamic changes …

The cytochrome bcc-aa 3 oxidase (Cyt-bcc) of Mycobacterium tuberculosis (Mtb) is a
promising anti-tuberculosis target. However, when Cyt-bcc is inhibited, cytochrome bd …

Multidrug-resistant tuberculosis (MDR-TB) is an infectious disease caused by
Mycobacterium tuberculosis which is resistant to at least isoniazid and rifampicin. This …

Clofazimine (CFZ), an old hydrophobic riminophenazine, has a wide range of
antimycobacterial activity ranging from leprosy to nontuberculous mycobacterial diseases …

The highly adaptive cellular response of Mycobacterium tuberculosis to various antibiotics
and the high costs for clinical trials, hampers the development of novel antimicrobial agents …

Abstract Background:/Question Nontuberculous mycobacteria (NTM) infections are
increasingly detected but difficult to cure given complex drug-resistance patterns. Select US …